PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31704822-1	2019	BACKGROUND/AIM: Lenvatinib is a potent inhibitor of receptor tyrosine kinases, targeting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), KIT, and RET.	lenvatinib	16-26	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	192-195	
30447042-3	2018	Here, we investigated the antitumor and immunomodulatory activities of lenvatinib (a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor alpha, KIT and RET) and the combined antitumor activity of lenvatinib plus anti-programmed cell death 1 (PD-1) antibody in the Hepa1-6 mouse HCC syngeneic model.	lenvatinib	71-81	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	274-277	
28912872-1	2017	Lenvatinib is an oral, multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor beta, RET and KIT.	lenvatinib	0-10	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	211-214